
Rejuvenate Bio Inc has raised $19.5M in total funding. The most recent round was Series A.
Rejuvenate Bio Inc is headquartered in San Diego, CA.
Chronic, age-related diseases such as osteoarthritis, heart disease, and cancer are described as the primary threat to longevity and quality of life in aging dogs, and the page notes six in ten Americans live with at least one chronic disease, a leading cause of death, disability, and healthcare cost.
Rejuvenate Bio develops gene therapies aimed at the root causes of aging to treat chronic conditions in both companion animals and humans.
The company is running trials in dogs (MVD Trial 2020 and MVD Trial 2026) as part of its approach, using naturally aging companion animals as part of its pipeline toward human treatments.
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 27, 2026.